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 1. Summary  
 
Title: Treatment Options of Post-Traumatic Stress Disorder 
Author: Borislav Pekez 
 
Post-traumatic stress disorder (PTSD) affects individuals that have experienced or 
witnessed a traumatic event and it affects approximately 7-8 % of the general 
population. Even more alarming is the PTSD prevalence in military personal 
throughout the world, with the PTSD prevalence in US combat veterans ranging from 
6 to 31%. Severe or untreated PTSD can lead to long- term complications and 
consequences, including comorbid substance abuse, increased rates of depression 
and suicide, therefore treatment and potential prevention is key. An exploration of 
numerous clinical trials concerning the treatment of PTSD is necessary to conclude 
what the gold standard treatment should be. Considering the fatal consequences 
that may occur if treatment is not provided, there is great importance in reviewing 
multiple clinical trials and concluding what the current treatment algorithm should be. 
PTSD and other psychiatric disorders are not just treated via traditional 
pharmaceutical ways, but can also involve non- pharmacological, including but not 
limited to yoga and other forms of exercise. This review aims to explore the current 
medical treatment and non-medical treatment of PTSD and the effectiveness and 
safety of the drugs involved.  
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 2. Sažetak 
 
Liječenje posttraumatskog stresnog poremećaja 
Borislav Pekez 
 
Posttraumatski stresni poremećaj (PTSP) se javlja u osoba koje su proživjele ili bile 
svjedokom traumatskog događaja, a zahvaća otprilike 7-8% osoba u općoj 
populaciji. Međutim, posebice zabrinjava činjenica da je prisustvo PTSP-a utvrđeno 
u čak 6 do 31% u Američkih ratnih veterana. Težak ili neliječeni PTSP može imati 
dugotrajne posljedice i komplikacije, poput zlouporabe sredstava ovisnosti, 
povećane stope obolijevanja od depresivnog poremećaja; stoga je liječenje PTSP-a 
od presudne važnosti. Neophodne su brojne kliničke studije u oboljelih od PTSP-a, 
kako bi se utvrdilo koji je zlatni standard liječenja ovog poremećaja. S obzirom na 
moguće teške posljedice u neliječenih osoba, bitan je sustavni pregled kliničkih 
studija da bi se sastavio algoritam liječenja. Cilj ovog preglednog rada je prikazati 
farmakološko i nefarmakološko liječenje PTSP-a, kao i učinkovitost i sigurnost 
lijekova kojima za sada raspolažemo. 
 
Ključne riječi: Posttraumatskog stresnog poremećaja, Liječenje 
 
  1 
3. Introduction: Post- traumatic Stress Disorder 
 
 Post-traumatic stress disorder (PTSD) is a psychiatry disorder that 
affects individuals that have experienced or witnessed a traumatic event and it 
affects approximately 7-8 people out of 100 people in the general population 
(1). Even more alarming is the PTSD prevalence in military personal 
throughout the world. The combat veterans of the United States of America 
(USA) have the direst statistical data on PTSD prevalence, which ranges from 
6 to 31% (2). Severe or untreated PTSD can lead to long- term complications 
and consequences, including comorbid substance abuse, increased rates of 
depression and suicide; therefore treatment is of utmost importance (3). 
Symptoms of PTSD vary from individual to individual and may include 
nightmares, anxiety and/or flashbacks to name a few (4). PTSD is categorized 
in diagnostic and statistical manual of mental disorders (DSM) 5, which is 
trauma- and stressor- related disorders (5). A diagnostic criterion for DSM-5 is 
exposure to a traumatic or stressful event. The diagnostic criteria for PTSD is 
divided into criterion A to criterion H. Criterion A requires the patient to have 
one of the following in regards to the event: “direct exposure, witnessing the 
trauma/event, learning that a relative or close friend was exposed, or indirect 
exposure to aversive details of the trauma, usually in the course of 
professional duties” (5). Criterion B requires the patient to have one of the 
following in regards to persistently re-experiencing the event: “unwanted 
upsetting memories, nightmares, flashbacks, emotional distress after 
exposure to traumatic reminders, or physical reactivity after exposure to 
traumatic reminders” (5). Criterion C requires the patient to have one of the 
following in regard to avoiding trauma-related stimuli after the trauma: 
“trauma- related thoughts or feelings or trauma-related reminders” (5). 
Criterion D requires the patient to have two of the following in regards to 
negative thoughts or feelings that began or worsened after the trauma: 
“inability to recall key features of the trauma, overly negative thoughts and 
assumptions about oneself or the world, exaggerated blame of self or others 
for causing the trauma, negative affect, decreased interest in activities, feeling 
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isolated, or difficultly experiencing positive affect” (5). Criterion E requires the 
patient to have two of the following related to the trauma- related arousal and 
reactivity that began or worsened after the trauma: “irritability or aggression, 
risky or destructive behavior, hypervigilance, heightened startle reaction, 
difficulty concentrating, or difficulty sleeping” (5). Criterion F requires that the 
symptoms last for more than 1 month (5). Symptoms may occur immediately, 
however full diagnostic criteria is usually not fulfilled until 6 months after the 
trauma, which is referred to as delayed specification. Criterion G requires that 
the symptoms cause distress or functional impairment in the individual’s social 
and/or occupation. Finally, criterion H states that the symptoms should not be 
due to medication, substance abuse or other illnesses. Also, dissociative 
specification means that in addition to meeting criteria for diagnosis, the 
patient experiences high levels of either depersonalization or derealization in 
reaction to trauma- related stimuli (5). Depersonalization is “experience of 
being an outside observer of or detached from oneself” (5), for example 
feeling as if this is not happening to themselves or them believing that they 
are dreaming. Derealization is “experience of unreality, distance or distortion” 
(5). Another classification is International Classification of Diseases (ICD) 
where PTSD is categorized under F43.1 (6).  
 A summary of the diagnostic criterion for PTSD is that an adult must 
have all the following for at least 1 month: “at least one re- experiencing 
symptom, at least one avoidance system, at least two arousal and reactivity 
symptoms and at least on cognition and mood symptom” (1). 
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4. Pathophysiology of PTSD 
 
 Various parts of the brain have been associated with PTSD. The 
amygdala is the part of the brain responsible for evaluating stress and 
deciding when to react. During a traumatic event, the amygdala detects 
danger and alerts the body by initiating the fight or flight response; it also is 
able to store the memory and stimuli associated with it, including sights, 
smells, and sounds to help detect the danger in future settings and lastly, 
when the danger passes, it can produce calming thoughts (7). Thus, PTSD 
symptoms associated with the amygdala are: anxiety, hypervigilance, 
avoidance of stimuli associated with the trauma, and being easily startled. (7). 
Thus, if the amygdala is overactive, as in the case of patients with PTSD, it’s 
purpose becomes counterproductive because it can interfere with sleep or 
being able to calm down in safe situations due to hypervigilance.  
 The hippocampus is responsible for memory formation and during a 
traumatic event is stores the memory of the trauma, it is also capable of 
retrieving it at a later time and it can calm the amygdala alarm circuit (7). 
Symptoms of PTSD associated with the hippocampus are: confusion, 
disorientation, recurring thoughts, nightmares, flashbacks, and difficulty 
sleeping (7). Impaired sleep with frequent nightmares is a common and 
extremely frustrating symptom in patients with PTSD. Despite the 
hippocampus having the ability to calm the amygdala it is not able to because 
the new “danger” is perceived as real.  
 Another part of the brain that can calm the amygdala when the danger 
is gone is the prefrontal cortex. PTSD symptoms associated with the 
prefrontal cortex include irritability, numbness, and avoidance. In patients with 
PTSD, the activity of the prefrontal cortex seems to be decreased which 
corresponds with the aforementioned symptoms of withdrawal and avoiding 
triggers of the trauma (7). As a summary, the “prefrontal cortex is unable to 
override the hippocampus, as it flashes a memory, so it cannot signal the 
amygdala that there is no real danger” (7).   
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Neuroimaging has shown that there are neurobiological changes in the 
brains of patients with PTSD, with three areas being the most affected: 
hippocampus, amygdala and the medial frontal cortex (8). The amygdala 
becomes over-reactive to stimuli associated with the trauma (sights, smells, 
etc) (8). Symptoms of hyper reactivity, including exaggerated startle response 
and flashbacks, may be related to the overactive amygdala but also the 
“failure of higher brain regions (hippocampus and medial frontal cortex) to 
dampen the exaggerated symptoms of arousal and distress” (8).  
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 There are various therapies available for PTSD. These include 
pharmacotherapies, including anti-depressants, and also non- prescription 
options, including yoga. Also, there are two routes to treatment: treating the 
diagnosis or the specific symptoms and in the following various treatment 
options will be discussed and detailed. The aim of the treatment is to diminish 
the symptoms associated with PTSD.  
 
(B) Pharmaceutical Treatment Options 
 
Records of war veterans diagnosed with PTSD in 2004 were examined 
and it was found that 80% received psychotropic medication, and among 
those 89% were given antidepressants, 61% anxiolytics/sedative-hypnotics, 
and 34% antipsychotics (9). Patients were more likely to receive 
pharmacotherapy if they sought mental health services more often or had 
comorbid psychiatric disorders (9). Further on, depending on the co-
morbidities, there are predictors to the use of medication. For example, if the 
co-morbidity was depressive disorders, then the patient was given 
antidepressants; if it was anxiety disorders, they were prescribed 
anxiolytic/sedative-hypnotic drugs; and if psychotic disorders, then they were 
prescribed antipsychotics (9). However, there was also prescriptions given 
unrelated to co-morbid diagnoses and that treatment was targeted at specific 
symptoms, including insomnia, anxiety, nightmares, rather than a diagnosis 
(9).  
Selective serotonin re-uptake inhibitors (SSRIs) are generally used as 
first line treatment, however it’s been found that only 60% of patients respond 
to it (10). PTSD is also often refractory to pharmacotherapy (10). In a double-
blind, placebo- controlled study, it was found that patients with PTSD that 
were given SSRIs with adjunctive olanzapine has statistically significant 
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greater reduction in measures of posttraumatic stress, depression and 
especially sleep disorders, thus suggesting to add atypical antipsychotics in 
treating SSRI-resistant PTSD (10). 
 A systematic review and meta- regression analysis concluded that 
there was a reduction in PTSD symptoms greatest with SSRIs and tricyclic 
antidepressants up into 11 weeks of treatment and then after, the other 
medication classes were significantly greater than them (2).  In combat 
veterans particularly, concurrent anxiety and depressive symptoms are often 
reported, which is further support for the use of SSRIs and tricyclic 
antidepressants. Evidence from the systematic review shows that the variety 
of pharmacotherapy may be lacking but that it does have a “positive, but 
modest, therapeutic effect on PTSD, anxiety, and depressive symptom 
severity, and it also successfully acts as a concurrent treatment for these 
symptoms among combat veterans” (2).  
 Martényi F. concluded that data supports the efficacy of SSRIs 
particularly in the civilian population, especially females, regardless of the 
trauma that they experienced (11). However, that treatment in combat- related 
PTSD was inconclusive or negative (11). For males that experienced combat- 
related trauma, improvement was found with fluoxetine, a SSRI, but that an 
adjuvant 5HT2 antagonist can improve the SSRI effect (11). Further on, 
nefaxodone, an atypical antidepressant, was better than placebo, however 
risperidone, an antipsychotic, added to an antidepressant “showed significant 
benefit compared to antidepressant monotherapy in the treatment of combat- 
related PTSD” (11). Despite the widespread prescription of different 
psychotropic agents in patients with PTSD (9), only two drugs are so far 
approved by regulatory agencies specifically for the treatment of PTSD: 
paroxetine and sertraline.  
 There has been some research on the use of anti-epileptics drugs 
(AEDs) as treatment to PTSD. In double-blind, placebo-controlled trials, AEDs 
that have been found to be effective are: lamotrigine, topiramate, and 
tiagabine (12). AEDs may be effective because some of them, including 
carbamazepine, lithium and valproate, interfere with limbic kindling. The 
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symptoms of PTSD may involve sympathetic nervous system hyper arousal 
and hyperactivity, which may include stress-induced limbic kindling (13). 
These symptoms include intrusive re-experiencing and increased arousal. An 
open clinical trial found that 10 out of 16 patients showed significant 
improvement while using Valproate, especially with hyper arousal/ hyper 
reactivity symptoms (13). 
 In the treatment of PTSD there will be individuals that respond to 
pharmacotherapy such as SSRI, AEDs, and antipsychotics, but on the other 
hand there are those that seem to be resistant to those types of treatments. A 
relatively controversial approach to treating PTSD is the rediscovered drug 
±3,4-methylenedioxymethamphetamine (MDMA), better known as Ecstasy, as 
a therapeutic adjunct. MDMA is a synthetic drug that alters perception and 
mood (14). According to the National Institute on Drug Abuse MDMA 
increases the activity of three neurotransmitters: Dopamine, Serotonin, and 
Norepinephrine (14). The article states that the effects of that are “euphoria 
and increased energy/activity…increases heart rate and blood 
pressure…affects mood, appetite, sleep” (14). Other effects on health that 
MDMA may have are nausea, blurred vision, chills, and muscle cramping 
(14). 
According to a 2011 randomized controlled study done by Mithoefer et 
al. prior to the criminalization in 1985 of the use of MDMA, it was used as a 
catalyst to psychotherapy (15). In their study, twenty patients who were 
resistant to psychopharmacology and psychotherapy were placed randomly 
into a control or experimental group. In the experimental group, twelve 
participants would go through psychotherapy with the active drug (MDMA) 
and the eight in the control group would be given an inactive placebo along 
with psychotherapy. The therapy sessions were done twice, each lasting eight 
hours in length. In the article it states, “Primary outcome measure was the 
Clinician-Administered PTSD Scale.” (15). This scale was utilized at baseline, 
4 days after the experimental session, and 2 months after the second session 
according to the article (15). In the study the participants also went through 
blood pressure, neurocognitive, and temperature testing since the dangers of 
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MDMA are still unknown in the therapeutic setting but the effects that the drug 
has on the body are well established and some of which were discussed 
above. In the study they state, “ There were no drug-related serious adverse 
events, adverse neurocognitive effects or clinically significant blood pressure 
increases” (15). The results of the study showed that the experimental group 
through out all three times of assessment had significantly lower scores on 
the clinician-administered PTSD scale, when compared to the control group 
(15). The clinical response of the control group and the experimental group 
were (25%) and (83%) respectively (15). As their final point in the study the 
authors stated “MDMA-assisted psychotherapy can be administered to 
posttraumatic stress disorder patients without evidence of harm” (15). This 
study is obviously very small and needs to be repeated with more participants 
in order to truly make a concrete conclusion. Also, other participants that don’t 
have treatment resistant PTSD need to be included in a future study to see 
how standard treatment methods such as SSRIs and antipsychotics compare 
in their effects on alleviating PTSD symptoms.  
 
(C) Non- Pharmaceutical Treatment Options  
 
A randomized control study done by van der Kolk et al. found that yoga 
can significantly reduce symptoms of PTSD (16). The symptoms that it 
specifically helps are the feelings of helplessness and fear. This is 
accomplished by the increase in emotional awareness and the affect 
tolerance that yoga provides (16). It found that these effects are even 
comparable to treatment of PTSD with pharmaceuticals (16). In another study, 
which was a long term follow up study performed by Rhodes, Spinazzola, and 
van der Kolk, it states that symptoms of PTSD were decreased and the 
potential loss of the PTSD diagnosis is linked with the greater frequency of 
practicing yoga (17).  
 Another treatment option that has potential is mindfulness-based 
stretching and deep breathing exercise (MBX). A randomised control study 
done by Kim et al. concluded that there is a significant reduction of PTSD-like 
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symptoms when utilizing MBX (18). They concluded this by not only utilizing 
the PTSD Checklist-Civilian version (PCL-C) but also through measuring 
cortisol levels. The participants in the experimental group did MBX for 8 
weeks in semi- weekly session of 6 minutes and felt benefits (18). Other 
interventions along the lines of the aforementioned treatment is meditation. A 
systemic review done by Lang et al. in 2012 covered the three major types of 
meditation which could be used as a form of treatment for PTSD: compassion 
meditation, mindfulness, and mantra (19). In their paper they stated “Empirical 
evidence of the efficacy of meditation for PTSD is very limited but holds some 
promise.” They go on to say that more evaluation is warranted to analyze the 
mechanism that improve quality of life and reduce the PTSD symptoms (19).  
Physical exercise is important for our physical and mental well-being. A 
randomized control trial done by Rosenbaum, Sherrington and Tiedemann 
discovered that not only does exercise improve sleep, reduce symptoms of 
depression and the waist circumference, it also reduces the symptoms of 
PTSD when it is paired with the usual treatment for PTSD (20). The usual 
treatment for this study was pharmacotherapy, psychotherapy and group 
therapy. The experimental group participants did 3 sessions of resistant 
training and for 30 minutes along with a pedometer based walking program 
along with the usual treatment as mentioned above (20).   
 Natural disasters such as earthquakes, tornadoes, and hurricanes can 
have devastating effects not only on the natural world around us but also on 
the mental health of individuals that survive these events. It is no wonder that 
some people got PTSD after experiencing an event like the earthquake that 
the people in the Sichuan Province China went through in 2008. A 
randomised control study was done by Chen et al. on adolescents who 
survived this disaster and lost parents to see if short term cognitive-
behavioural therapy (CBT) was effective at treating PTSD and depression 
(21). Short-term cognitive behavioural therapy was compared to general 
supportive interventions and control group of no treatment. According to the 
study “CBT was effective in reducing PTSD and depressive symptoms and 
improved psychological resilience” (21). They go on further to say that the 
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only improvement that the general supportive intervention provided was 
psychological resilience (21).   
 Mother nature isn’t the only force to be reckoned with when it comes to 
mental health. Man made conflicts, such as war, leave many people displaced 
from their country of origin to live a life as refugees all over the world. This 
again leaves many people to battle with the world around them along with the 
strain that it takes on their mental health, leading some to be diagnosed with 
PTSD. The Syrian refugees are no exception. Acarturk et al. wanted to 
explore if an effective treatment for PTSD was eye movement desensitization 
and reprocessing (EMDR) (23). According to Shapiro and the review that the 
author did “Eye movement desensitization and reprocessing (EMDR) therapy 
is an empirically validated treatment for trauma, including such negative life 
experiences as commonly present in medical practice” (22). Acarturk et al. set 
up a randomized trail where the experimental group received EMDR and the 
control group was put in a wait-list condition (23). The outcome of the study 
was measured utilizing the Event Scale-Revised (IES-R) and Beck 
Depression Inventory after the 4 week follow up (23). Post treatment scores 
showed that the EMDR group had significantly lower scores when compared 
to the control group. Additionally the EMDR group also had lower depression 
scores when compared to the control group (23).  
 A systemic review done in 2007 by Bisson and Andrew analyzed the 
literature on the topic of psychological treatments of PTSD. The authors 
pulled randomized control studies that contained treatment types of trauma-
focused cognitive behavioural therapy/exposure therapy (TFCBT), stress 
therapy, and others such as supportive and hypnotherapy, to mention a few 
(24). After all the analysis was done they came to the conclusion that an 
effective psychological treatment in reducing PTSD symptoms is stress 
management and both individual and group TFCBT (24). According to the 
article the evidence suggests individual TFCBT is superior in treating PTSD 
symptoms when compared to stress management between 2 and 5 months 
following treatment. They also go on to state, “Other non-trauma focused 
psychological treatments did not reduce PTSD symptoms as significantly” 
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(24). Interestingly the authors brought up the question of if there is a harmful 
impact that psychological treatment may have on people diagnosed with 
PTSD. The evidence for this question to be answered will have to be explored 
in another research paper because in this systemic review the evidence was 
insufficient.  
  12 
6. Prophylactic treatment of PTSD 
 
 Aforementioned, treatment of PTSD includes potential adjunctive 
therapies to current pharmacotherapy algorithms once symptoms have 
developed and a diagnosis is established. Prophylactic treatment would be 
started prior to symptoms developing. However, an early obstacle is the fact 
that not everyone who experiences a traumatic event will develop PTSD and 
of course, unnecessary treatment should be avoided (25). 
 There are a number of markers that have been proposed to distinguish 
patients that are at a risk of developing PTSD: lower cortisol levels, increased 
heart rate dynamics after traumatic event or somatic arousal (26, 27).  
 Another issue in prophylactic treatment is the desire to counteract the 
development of PTSD while not disturbing normal functioning (25).  
 There are various forms of prophylactic treatment. In those patients in 
risk populations, such as soldiers, this is termed prospective or primary 
prevention and treatment is given immediately after the trauma (25). If 
treatment is given later but before “induction or consolidation of processes 
leading to PTSD” then this is retrospective or secondary prevention and this 
broadens the amount of patients, including those in lower risks where trauma 
did occur, for example following a car accident (25).  
 In regards to primary prevention, one strategy is to enhance the 
patient’s stress coping and preclinical studies have demonstrated that rats 
exposed to single prolonged stress (SPS) showed increased inhibition of the 
hypothalamo-pituitary-adrenal (HPA) axis and increased expression of 
glucocorticoid receptor (GR) in the hippocampus (28).  
 In regards to secondary prevention, in another study performed on rats, 
it was found that microinjection of anisomycin, a protein synthesis inhibitor, 
prior to and after stress exposure decreased symptoms of anxiety and also 
avoidant behavior, reduced startle response (29). Therefore, disrupting the 
“process of traumatic memory consolidation may be useful” in decreasing the 
progression and amplitude of symptoms of PTSD (29). An obvious limitation 
to this is that injection of any pharmacologicals are not possible if the 
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traumatic event is not foreseeable. However, further studies researching this 
topic should be performed on humans to see the efficacy.  
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7. Conclusion 
  
Everyone is an individual; everyone sees the world differently and 
everyone’s mind works differently, thus we have people who get PTSD, while 
others do not, despite going through a similar traumatic event.  
Current treatment algorithms, in regards to pharmacotherapy, use 
selective serotonin reuptake inhibitors as first line treatment, however with 
resistance and potential negative side effects, other drugs that are being used 
in conjunction with SSRIs, or instead of, include tricyclic antidepressants, anti- 
epileptics, antipsychotics, atypical antidepressants, and/or NMDA.  
In addition, or instead of, there are many non- pharmacological 
treatment options of PTSD. These include yoga, meditation, MBX, cognitive 
behavioral therapy, and EDRM. With many of these since there are no or 
limited negative side effects, perhaps it is useful to try in all patients suffering 
with PTSD since there is a potential for positive effects. In a worst- case 
situation where the patient receives no benefit from any of the non- 
pharmacological treatments, the negative effects are minor at worst.  
It is also important to monitor the development and/or progression of 
PTSD in individuals in high- risk groups, for example soldiers in war or abuse 
victims. Perhaps, examining neuroimaging of individuals in risk groups may 
help in noticing the developing and progression from the aforementioned 
neuroimaging changes that occur in individuals - in the amygdala, 
hippocampus and frontal cortex.  
The main conclusion that can be drawn is that it is vital to personalize 
the treatment for each patient and also what trauma they experienced. 
Combining therapies is a possibility, which for some might include 
pharmacotherapy to stabilize the patient and then to explore possible further 
treatment. 
With the world being in such a seemingly chaotic state currently, it is 
easy to assume that more and more people will be suffering and specifically 
suffering from PTSD due to these negative events, be they natural or man-
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made. Therefore, it is upmost importance that more research and more 
funding is allocated for PTSD treatments.  
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